Bronchogen
Also known as: Lung Peptide Bioregulator, Bronchial Bioregulator
A Khavinson bioregulator peptide targeting respiratory and bronchial tissue health.
Overview
Bronchogen is a short synthetic peptide from the Khavinson bioregulator family designed to support lung and bronchial function. It is used in Russia for respiratory conditions and may help restore normal function in damaged pulmonary tissue.
Mechanism of Action
Gene regulatory effects on bronchial and pulmonary epithelium. Proposed to normalize protein synthesis in respiratory tissues. May support mucociliary clearance and epithelial repair.
Pharmacokinetics
Small peptide allows oral/sublingual administration. Tissue-specific effects on respiratory system.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Maintenance
10-20 mg
1-2x daily
10-30 days
2-3 courses per year
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Improved respiratory function in COPD patients
- 2Enhanced mucociliary clearance
- 3Reduced frequency of respiratory infections
- 4Gene expression modulation in lung tissue
Side Effects & Contraindications
Reported Side Effects
- Generally well-tolerated
Contraindications
- Acute pulmonary infections (treat first)
Safety Considerations
Generally well-tolerated. Limited Western clinical data. May be used alongside standard treatments.
Storage Requirements
Store at room temperature
Scientific References
- 1